tradingkey.logo
tradingkey.logo
検索

Evotec SE

EVO
ウォッチリストに追加
1.530USD
-0.010-0.65%
終値 09-24 16:00(ET)
543.75M時価総額
損失額直近12ヶ月PER

Evotec SEについて 企業名

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Evotec SE プロフィール

企業コードEVO
会社名Evotec SE
上場日Oct 11, 1999
最高経営責任者「CEO」Wojczewski (Christian)
従業員数4827
証券種類Depository Receipt
決算期末Oct 11
本社所在地Essener Bogen 7
都市HAMBURG
証券取引所NASDAQ OMX - NASDAQ BASIC
国Germany
郵便番号22419
電話番号4940560810
ウェブサイトhttps://www.evotec.com/
企業コードEVO
上場日Oct 11, 1999
最高経営責任者「CEO」Wojczewski (Christian)

Evotec SEの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Cord Dohrmann, Ph.D.
Dr. Cord Dohrmann, Ph.D.
Chief Scientific Officer, Member of the Management Board
Chief Scientific Officer, Member of the Management Board
--
--
Mr. Roland Sackers
Mr. Roland Sackers
Independent Vice Chairman of the Supervisory Board
Independent Vice Chairman of the Supervisory Board
--
--
Dr. Constanze Ulmer-Eilfort
Dr. Constanze Ulmer-Eilfort
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Ms. Camilla Macapili Languille
Ms. Camilla Macapili Languille
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mrs. Aurelie Dalbiez
Mrs. Aurelie Dalbiez
Chief People Officer, Member of the Management Board
Chief People Officer, Member of the Management Board
--
--
Dr. Christian Wojczewski
Dr. Christian Wojczewski
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Duncan Mchale
Dr. Duncan Mchale
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Wesley Wheeler
Mr. Wesley Wheeler
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Ashiq H. Khan
Dr. Ashiq H. Khan
Chief Commercial Officer, Member of the Management Board
Chief Commercial Officer, Member of the Management Board
--
--
Mr. Dieter Weinand
Mr. Dieter Weinand
Chairwoman of the Supervisory Board
Chairwoman of the Supervisory Board
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Cord Dohrmann, Ph.D.
Dr. Cord Dohrmann, Ph.D.
Chief Scientific Officer, Member of the Management Board
Chief Scientific Officer, Member of the Management Board
--
--
Mr. Roland Sackers
Mr. Roland Sackers
Independent Vice Chairman of the Supervisory Board
Independent Vice Chairman of the Supervisory Board
--
--
Dr. Constanze Ulmer-Eilfort
Dr. Constanze Ulmer-Eilfort
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Ms. Camilla Macapili Languille
Ms. Camilla Macapili Languille
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mrs. Aurelie Dalbiez
Mrs. Aurelie Dalbiez
Chief People Officer, Member of the Management Board
Chief People Officer, Member of the Management Board
--
--
Dr. Christian Wojczewski
Dr. Christian Wojczewski
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--

よくある質問

Evotec SEの上位5名の株主は誰ですか?

Evotec SEの上位5名の株主は以下のとおりです。Dr. Cord Dohrmann, Ph.D.

Evotec SE(EVO)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Evotec SEの株式を保有している機関は81社あり、保有株式の総市場価値は約9.58Mで、全体の2.69%を占めています。2025Q4と比較して、機関の持ち株は-584606.00増加しています。
tradingkey.logo
リスク告知:当社ウェブサイト及びモバイルアプリは特定の投資商品に関する一般的な情報のみを提供しており、Finsightsは金融アドバイスや投資商品の推奨を行うものではありません。本情報の提供をもってFinsightsが投資助言を行っていると解釈されることはありません。
投資商品には元本割れを含む重大なリスクが伴い、全ての投資家に適するものではありません。なお、過去の運用実績は将来の成果を保証するものではありません。
Finsightsは、第三者広告主または提携先が当社ウェブサイト・モバイルアプリ上に広告を掲載することを許可する場合があり、これら広告主から広告への反応に基づく報酬を受けることがあります。
© 著作権: FINSIGHTS MEDIA PTE. LTD. 無断複写・転載を禁じます。